navitoclax,ruxolitinib
abbvie,novartis,incyte
['jakafi', 'rova', 'navitoclax', '$abbv']
note r/r navitoclax + jakafi data were published in jco last year. both settings now in ph3 (transform-1 &amp; 2 trials). $abbv expects fda approval in 2023, per q4 deck #asco2022
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.